GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Cyclically Adjusted Revenue per Share

Amgen (XSGO:AMGN) Cyclically Adjusted Revenue per Share : $39.27 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Amgen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amgen's adjusted revenue per share for the three months ended in Dec. 2023 was $15.234. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $39.27 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Amgen's average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amgen was 33.60% per year. The lowest was 9.80% per year. And the median was 15.65% per year.

As of today (2024-04-29), Amgen's current stock price is $255.16. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $39.27. Amgen's Cyclically Adjusted PS Ratio of today is 6.50.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 9.60. The lowest was 5.09. And the median was 7.31.


Amgen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Amgen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted Revenue per Share Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.63 35.19 41.36 39.74 39.27

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.74 44.34 49.37 41.59 39.27

Competitive Comparison of Amgen's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.



Amgen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=15.234/129.4194*129.4194
=15.234

Current CPI (Dec. 2023) = 129.4194.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.887 99.695 7.642
201406 6.745 100.560 8.681
201409 6.525 100.428 8.409
201412 6.897 99.070 9.010
201503 6.536 99.621 8.491
201506 6.992 100.684 8.988
201509 7.491 100.392 9.657
201512 7.256 99.792 9.410
201603 7.272 100.470 9.367
201606 7.524 101.688 9.576
201609 7.717 101.861 9.805
201612 8.039 101.863 10.214
201703 7.374 102.862 9.278
201706 7.873 103.349 9.859
201709 7.876 104.136 9.788
201712 7.992 104.011 9.944
201803 7.812 105.290 9.602
201806 9.180 106.317 11.175
201809 9.097 106.507 11.054
201812 9.719 105.998 11.867
201903 8.877 107.251 10.712
201906 9.625 108.070 11.526
201909 9.530 108.329 11.385
201912 10.380 108.420 12.390
202003 10.372 108.902 12.326
202006 10.483 108.767 12.473
202009 10.905 109.815 12.852
202012 11.360 109.897 13.378
202103 10.157 111.754 11.763
202106 11.330 114.631 12.792
202109 11.765 115.734 13.156
202112 12.138 117.630 13.355
202203 11.321 121.301 12.079
202206 12.279 125.017 12.711
202209 12.364 125.227 12.778
202212 12.712 125.222 13.138
202303 11.348 127.348 11.533
202306 13.009 128.729 13.079
202309 12.831 129.860 12.788
202312 15.234 129.419 15.234

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Amgen  (XSGO:AMGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=255.16/39.27
=6.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 9.60. The lowest was 5.09. And the median was 7.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amgen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (XSGO:AMGN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Cyclically Adjusted Revenue per Share
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (XSGO:AMGN) Headlines

From GuruFocus

Q4 2022 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Evercore ISI HealthCONx Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc ESMO Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024